Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Rating of “Hold” by Analysts

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has been assigned an average recommendation of “Hold” from the seven research firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $5.8333.

Several research firms have commented on ZNTL. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research report on Tuesday, April 7th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Zentalis Pharmaceuticals in a report on Friday, May 22nd. Wall Street Zen raised shares of Zentalis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Sunday, May 31st. Guggenheim raised their price target on shares of Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, April 10th. Finally, Wells Fargo & Company began coverage on shares of Zentalis Pharmaceuticals in a report on Tuesday, March 17th. They issued an “equal weight” rating and a $5.00 price target for the company.

Zentalis Pharmaceuticals Stock Up 6.6%

ZNTL stock opened at $4.04 on Friday. Zentalis Pharmaceuticals has a 12 month low of $1.13 and a 12 month high of $6.95. The firm has a market cap of $287.59 million, a P/E ratio of -2.34 and a beta of 1.96. The company’s 50-day moving average price is $3.95 and its two-hundred day moving average price is $3.00.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its earnings results on Tuesday, May 12th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.01). Equities analysts predict that Zentalis Pharmaceuticals will post -1.92 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ZNTL. AQR Capital Management LLC raised its position in Zentalis Pharmaceuticals by 177.6% in the 1st quarter. AQR Capital Management LLC now owns 619,330 shares of the company’s stock valued at $985,000 after buying an additional 396,233 shares during the last quarter. Millennium Management LLC lifted its stake in Zentalis Pharmaceuticals by 220.6% in the first quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock valued at $4,881,000 after purchasing an additional 2,111,951 shares during the last quarter. Qube Research & Technologies Ltd purchased a new position in Zentalis Pharmaceuticals in the second quarter valued at approximately $37,000. Sei Investments Co. lifted its stake in Zentalis Pharmaceuticals by 373.1% in the second quarter. Sei Investments Co. now owns 167,100 shares of the company’s stock valued at $194,000 after purchasing an additional 131,780 shares during the last quarter. Finally, Jane Street Group LLC lifted its stake in Zentalis Pharmaceuticals by 346.3% in the second quarter. Jane Street Group LLC now owns 664,061 shares of the company’s stock valued at $770,000 after purchasing an additional 515,257 shares during the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.